IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), a subsidiary of IQ-AI, has completed the first installation of its bundled technologies in partnership with Prism Clinical Imaging at a major Southeastern US health system.
Prism is a specialist in brain mapping software and applications and the partnership with IB combines their brain mapping and analysis tools for clinical use in diagnosis and guiding treatment.
IB and Prism tool suite helps clinicians treat brain tumour patients by identifying structures to avoid when navigating to a tumour site (Prism) and, once there, distinguishing between aggressive tumour and non-tumour tissue (IB) to aid biopsy and tumour resection planning.
The aim is to allow neurosurgeons to plan the safest and optimal surgical approach.